← Back to Clinical Trials
Recruiting NCT06329076

Losartan Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Trial Parameters

Condition Healthy
Sponsor University of Electronic Science and Technology of China
Study Type INTERVENTIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 18 Years
Max Age 40 Years
Start Date 2024-03-05
Completion 2025-06-01
Interventions
LosartanPlacebo

Brief Summary

The main aim of the present study is to investigate the effects of orally administered losartan on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Eligibility Criteria

Inclusion Criteria: * Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent. * Normal or corrected-normal version Exclusion Criteria: * History of neuropsychiatric diseases. * History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness. * History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction. * History of renal diseases, including renal stones or renal failure. * History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus * Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food. * Infections such as COVID-19 or influenza, or unexplained fever. * Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg). * His

Related Trials